Hologic Inc (HOLX) Growth Rates Comparisons to Medical Laboratories Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Hologic Inc  (NASDAQ: HOLX)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

Hologic Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HOLX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) 44.84 % 11.11 % 8.07 % 9.17 %
Q / Q Revenue Growth (Q4 MRQ) -46.45 % 1.31 % 1.81 % 4.22 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) 12.61 % 6.47 % 7.04 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) 8.35 % 1.92 % 3.51 % 2.08 %
Revenue 5 Year Average Growth -0.41 % 13.12 % 8.65 % 10.59 %


HOLX's Growth Comparisons in I. Quarter 2025




Hologic Inc showed respectable 44.84% year on year rise of Revenue in the first quarter 2025, comparing favorably to the 11.11% rise in the Medical Laboratories industry, and 8.07% growth in the Healthcare sector. Comparing the first quarter sales growth, both Medical Laboratories industry and Hologic Inc outperformed 9.17% overall market increase.

Top-line fell by -46.45% from the fourth quarter results. Comparing the annual growth, sales of -0.41% on average in last five years, to the S & P 500's, including only Businesses with the first quarter 2025 financial results, average yearly sales growth is 10.59%. Hologic Inc grew less than the market.

HOLX Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
United States
-0.54 %
-
International
3.94 %
-
Diagnostics
-1.32 %
-
Diagnostics United States
-0.88 %
-
Diagnostics International
-2.5 %
-
Diagnostics Cytology Perinatal
1.12 %
-
Diagnostics Cytology Perinatal United States
0 %
-
Diagnostics Cytology Perinatal International
2.83 %
-
Diagnostics Molecular Diagnostics
-3.49 %
-
Diagnostics Molecular Diagnostics United States
-2.78 %
-
Diagnostics Molecular Diagnostics International
-5.86 %
-
Diagnostics Blood Screening
104.88 %
-
Diagnostics Blood Screening United States
104.88 %
-
Breast Health
1.84 %
-
Breast Health United States
3.23 %
-
Breast Health International
-2.64 %
-
Breast Health Breast Imaging
-0.57 %
-
Breast Health Breast Imaging United States
1.95 %
-
Breast Health Breast Imaging International
-8.8 %
-
Breast Health Interventional Breast Solutions
9.6 %
-
Breast Health Interventional Breast Solutions United States
7.39 %
-
Breast Health Interventional Breast Solutions International
16.51 %
-
GYN Surgical
8.72 %
-
GYN Surgical United States
5.74 %
-
GYN Surgical International
16.89 %
-
Skeletal Health
68.99 %
-
Skeletal Health United States
22.12 %
-
Skeletal Health International
186.67 %
-
Europe
5.48 %
-
Asia-Pacific
-8.47 %
-
Rest of World
1.89 %
-
Disposables
-2.94 %
-
Capital equipment components and software
21.4 %
-
Service
6.24 %
-
Other
1.89 %
-
Total
44.84 %
-73.03 %


Growth Rates of HOLX's Income in the first quarter 2025


HOLX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) 3.13 % 3.74 % 27.58 % 29.95 %
Sequential Operating Income Change (Q4 MRQ) 0.04 % -7.28 % -17.34 % 4.5 %
Y / Y Operating Income Growth (Q4 TTM) 5.45 % 68.48 % 37.03 % 14.37 %
Sequential Operating Income Growth (Q4 TTM) 1.01 % 15.03 % 9.74 % 6.96 %
Operating Income 5 Year Avg. Change -8.36 % 6.34 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) -10.9 % -74.8 % - 21.83 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) -4.33 % -27.4 % - 11.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) -26.91 % -39.26 % -25.13 % 16.46 %
Sequential Income from Cont. Ops. Change (Q4 TTM) -3.87 % -24.71 % -6.43 % 6.05 %
Income from Cont. Ops. 5 Year Avg. Change -12.62 % 5.07 % 0.17 % -28.52 %

HOLX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) -10.9 % 46.12 % 16.75 % 21.56 %
Q / Q Net Income Growth (Q4 MRQ) -4.33 % -27.26 % -34.6 % 11.12 %
Y / Y Net Income Change (Q4 TTM) -26.91 % 8.93 % 32.74 % 16.59 %
Sequential Net Income Change (Q4 TTM) -3.87 % 58.22 % 7.31 % 6.03 %
Net Income 5 Year Avg. Growth -12.62 % 5.34 % 9.21 % 22.96 %

HOLX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) -8.05 % -75.82 % - 21.83 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) -4.17 % -27.3 % - 11.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) -23.75 % - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) -2.81 % - - -99.7 %
EPS from Cont. Ops. 5 Year Avg. Growth -10.03 % -8.23 % 0.17 % -28.52 %



HOLX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) -9.2 % 40.22 % 16.75 % -28.52 %
Q / Q EPS Net Growth (Q4 MRQ) -3.66 % -27.16 % -34.6 % 11.12 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - -99.97 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) -3.24 % - - -99.87 %
EPS Net 5 Year Avg. Change -9.97 % 5.34 % 9.21 % 22.96 %



Although the Medical Laboratories industry saw advancing EPS by 40.22%, Hologic Inc announced -9.2% year on year income per share decline in the first quarter, to $ 0.79, and underperformed the 16.75% EPS improvement in the Healthcare sector. Comparing first quarter, income per share Hologic Inc was trailing overall market not just Medical Laboratories industry.

the bottom-line fell by -3.66% from the fourth quarter. Average annual income per share growth for Hologic Inc is -9.97%, while S & P 500's average yearly income per share increase is 22.96%, including only Businesses with the first quarter 2025 earnings.

HOLX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) 36.98 % -25.07 % -10.43 % 2 %
Sequential Free Cash Flow Change (Q4 MRQ) -36.97 % -8.23 % -28.82 % 22.32 %
Y / Y Free Cash Flow Change (Q4 TTM) -10.46 % 18.54 % 11.09 % 11.81 %
Sequential Free Cash Flow Change (Q4 TTM) 5.91 % -2.51 % 1.93 % 2.41 %
Free Cash Flow 5 Year Avg. Change 4.25 % 10.39 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - - -90.24 % 1035.72 %
Sequential Net Cash Flow Change (Q4 MRQ) -7.04 % 28.43 % -99.01 % -
Y / Y Net Cash Flow Change (Q4 TTM) - 110.21 % -23.28 % -
Sequential Net Cash Flow Change (Q4 TTM) - 182.1 % -25.11 % -
Net Cash Flow 5 Year Avg. Change - -9.51 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) -54.35 % 24.59 % 9.45 % 23.41 %
Sequential Capital Expenditures Change (Q4 MRQ) 7.3 % 41.29 % 18.78 % 18.97 %
Y / Y Capital Expenditures Change (Q4 TTM) -38.3 % 9.96 % 10.57 % 23.88 %
Sequential Capital Expenditures Change (Q4 TTM) -23.58 % 8.68 % 6.56 % 7.02 %
Capital Expenditures 5 Year Avg. Change -5.47 % 8.7 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.